跳至主要内容
临床试验/NCT03362112
NCT03362112已完成不适用

Lipoprotein-associated Phospholipase A2 in Patients With Type 2 Diabetes

Nanjing First Hospital, Nanjing Medical University0 个研究点目标入组 1,713 人开始时间: 2015年1月30日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
1,713
主要终点
Lipoprotein-associated Phospholipase A2

研究概览

简要总结

Lipoprotein-associated phospholipase A2 (LP-PLA2) is a good marker of cardiovascular risk and inflammation. This study aims at the characteristic and clinical significance of LP-PLA2 test in patients with type 2 diabetes(T2D).

详细描述

The investigators recorded clinical factors, serum levels of glucose, HbA1c, lipids and LP-PLA2 in patients with T2D who visited in the Department of Endocrinology at the Nanjing First Hospital from January 2015 to August 2016. The relationship between levels of LP-PLA2 and diabetic complications are analysed.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients with T2D and the diagnostic criteria of T2D is according to the World Health Organization in 1999.

排除标准

  • Patients use systemic steroidal anti-inflammatory drugs.
  • Patients are pregnant.
  • Patients with an acute infection.

结局指标

主要结局

Lipoprotein-associated Phospholipase A2

时间窗: Day one

the plasma lipoprotein-associated phospholipase A2 level of patients

次要结局

  • C Peptide(Day one)
  • Diabetic Complication(Day one)
  • HbA1c(Day one)
  • LDL-c(Day one)

研究者

申办方类型
Other
责任方
Sponsor

相似试验

Lipoprotein-associated Phospholipase A2 in Patients... | 临床试验